The results of therapy for 78 patients with disseminated renal cell carcinoma are evaluated. Symptoms related to the primary tumor were noted in only 28 per cent of the patients and were not difficult to manage in those patients not undergoing nephrectomy. Adjuctive nephrectomy, therefore, is a more appropriate term than palliative nephrectomy when referring to removal of the primary tumor as part of an aggresive combined therapeutic approach. Of patients receiving an adjunctive nephrectomy those with osseous metastases only had a better 1-year survival rate (36 per cent) than those with metastases to other sites (18 per cent). Complete regression of metastases was noted in 12 per cent of patients treated with medroxyprogesterone acetate and adjunctive nephrectomy. The role of adjunctive nephrectomy combined with embolic infarction, hormonal therapy, chemotherapy and/or immunotherapy is discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0022-5347(17)58429-3 | DOI Listing |
Radiographics
January 2025
From the Departments of Radiology (L.C.J., P.J.N., D.A., S.M.T., E.T., G.S., T.P., S.K.V., T.D.A.), Urology (A.M.P.), and Radiation Oncology (B.S.), Mayo Clinic, 200 First St SW, Rochester, MN 55905.
In patients with renal masses, when intervention is warranted, partial nephrectomy is preferred when feasible, especially for T1 renal masses. Thermal ablation, however, has become an accepted alternative treatment of small renal neoplasms with excellent oncologic outcomes. The National Comprehensive Cancer Network guidelines include thermal ablation as a treatment strategy for managing T1a and select T1b masses.
View Article and Find Full Text PDFClin Genitourin Cancer
November 2024
Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Introduction: Management of metastatic renal cell carcinoma (mRCC) is highly individualized and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal sequencing of CN and ST is uncertain. A difference in perioperative outcomes based on sequence of CN and ST could influence decisionmaking.
View Article and Find Full Text PDFCureus
October 2024
Department of Urology, Doctor's Hospital at Renaissance Health, Edinburg, USA.
Sarcomatoid renal cell carcinoma (sRCC) is a form of renal cancer known for its aggressiveness and poor prognosis. This report presents the case of a 65-year-old male with an unusual presentation of sRCC. The patient presented with worsening kidney function, flank pain, hematuria, fatigue, and weight loss.
View Article and Find Full Text PDFCureus
November 2024
Department of Urology, University Hospitals Birmingham, Birmingham, GBR.
Renal cell carcinoma accounts for the sixth most common cancer in the United Kingdom. With the increasing application of cross-sectional imaging, the frequency of incidental renal masses has increased over time. Laparoscopic and robot-assisted partial nephrectomy has become the standard of care in the management of size and stage-appropriate renal masses.
View Article and Find Full Text PDFUrol Case Rep
September 2024
Erlanger Department of Urology, College of Medicine, The University of Tennessee-Chattanooga, Chattanooga, TN, USA.
Renal Leiomyosarcoma (LMS) is an exceptionally rare and aggressive form of RCC (renal cell carcinoma), comprising of 0.5-1% of all adult RCC. This disease constitutes a 5-year 25 % overall survival.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!